FATE Fate Therapeutics Inc
6,088
$3.65
$0.05
(1.35%)
| Watchers | 6,088 |
| 52-Wk Low | $1.63 |
| 52-Wk High | $8.83 |
| Market Cap | $415.49M |
| Volume | 1.43M |
| 52-Wk High | $8.83 |
| 52-Wk Low | $1.63 |
Forecasting The Future: 8 Analyst Projections For Fate TherapeuticsBenzinga • 17 days ago
Latest Ratings for FATE
DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Dec 2021Morgan StanleyMaintainsEqual-Weight Dec 2021WedbushUpgradesNeutralOutperform
View More Analyst...
Share to Feed
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics ) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...
This indicator may be signaling that FATE's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received an average rating of "Hold" from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One...
A month has gone by since the last earnings report for Amicus Therapeutics (FOLD). Shares have lost about 8.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...
Fate Therapeutics (NASDAQ:FATE Get Free Report) had its target price boosted by equities research analysts at Bank of America from $2.00 to $6.00 in a report issued on Thursday, Benzinga...
It has been about a month since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...
This indicator may be signaling that FATE's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement...